| Literature DB >> 9891546 |
T Hirashima1, M Takada, T Komiya, T Nitta, K Masashi, N Masuda, K Matui, M Kikui, T Yasumitsu, I Kawase.
Abstract
Between July 1991 and February 1993, CYFRA 21-1 levels of 149 newly diagnosed patients with histologically proven non-small cell lung cancer (NSCLC) at Osaka Prefectural Habikino Hospital were measured with an enzyme immunoassay method developed by Boeringer Mannheim (Enzymun-Test CYFRA 21-1). NSCLC patients with CYFRA 21-1 serum levels over 3.5 ng/ml had a significantly poorer prognosis than did patients with normal CYFRA 21-1 levels (P < 0.001). Univariate analysis revealed that CYFRA 21-1 levels above 3.5 ng/ml, poor PS, advanced stage and serum LDH over 450 U/l strongly correlated with survival period. In multivariate analysis, however, only CYFRA 21-1 was found to be an independent prognostic factor compatible with Stage and PS (P = 0.0040 for CYFRA 21-1, P < 0.001 for PS, P = 0.0052 for Stage).Entities:
Mesh：
Substances：
Year: 1998 PMID： 9891546
Source DB: PubMed Journal: Anticancer Res ISSN： 0250-7005 Impact factor: 2.480